e largest completed pivotal clinical program and now the longest extension study reported in this disease to date.”



BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.

GLOBAL HEAD OF R&D

GALDERMA










Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2-5IL-31 is a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis.2-5Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the U.S. and EU.4,5

Media can find more information and resources on prurigo nodularis inthis toolkit.

About Nemluvio
Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive r
=*=*=*=*=*=
当前为第5/12页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页